Progressive loss of anti-HER2 CD4(+) T-helper type 1 response in breast tumorigenesis and the potential for immune restoration (Q36107949)

12 August 2017

Progressive loss of anti-HER2 CD4(+) T-helper type 1 response in breast tumorigenesis and the potential for immune restoration (English)

1 reference

12 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Rosemarie Mick

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Brian J Czerniecki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Elizabeth Fitzpatrick

object named as

Elizabeth Fitzpatrick

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Rachel R Kelz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Cinthia Rosemblit

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Erik Berk

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Lori Showalter

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Prachi Namjoshi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Kathreen P Lee

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Andrew M Brod

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Rachel L Yang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Clifford Hoyt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Michael D Feldman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Paul J Zhang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Shuwen Xu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Gary K Koski

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

1 April 2015

1 reference

12 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

e1022301

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

describes a project that uses

4 June 2020

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC4589053/fullTextXML

based on heuristic

inferred from PubMed Central ID database lookup

cites work

Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

CD4⁺ follicular helper T cell infiltration predicts breast cancer survival

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Dendritic cell-based vaccines: barriers and opportunities

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

2 October 2017

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Inhibition of ErbB2 by Herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Resistance to Trastuzumab in Breast Cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Effects of HER2 overexpression on cell signaling networks governing proliferation and migration

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

HER2/neu in the management of invasive breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Molecular portraits of human breast tumours

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

T cell-dependent B cell activation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Pathological features and prognosis of different molecular subtypes of breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589053

Multiplexed characterization of cancer immune response in FFPE biopsies - initial performance of a new approach

21 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1080%2F2162402X.2015.1022301

Detection of low-frequency antigen-specific IL-10-producing CD4(+) T cells via ELISPOT in PBMC: cognate vs. nonspecific production of the cytokine

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26451293

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26451293

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1080/2162402X.2015.1022301

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

PubMed publication ID

26451293

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26451293%20AND%20SRC:MED&resulttype=core&format=json